Skip to content

Clinical study on Acupuncture treatment of Hypertension with Hyperactivity of liver-Yang

Clinical study on Acupuncture treatment of Hypertension with Hyperactivity of liver-Yang

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037444
Enrollment
Unknown
Registered
2020-08-28
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

essential hypertension

Interventions

Sponsors

Dongzhimen Hospital of Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years old male and female; 2. In accordance with the diagnostic criteria of essential hypertension in the 2018 revised Chinese guidelines for the Prevention and treatment of Hypertension, patients with grade 1 and 2 low, moderate and high-risk hypertension have regularly taken less than 2 kinds of antihypertensive drugs for more than 2 months, and their blood pressure is stable at the normal high value without much fluctuation. The main object of study was (SBP >=130 mmHg, DBP >=80 mmHg); 3. meet the diagnostic standard of hyperactivity of liver-yang in hypertension; 4. They have not received acupuncture treatment in the past one month; 5. It has a correct understanding of the significance of the clinical research and has a good compliance with the observation and evaluation of the researchers; 6. The informed consent form was signed by the patient himself or by the immediate family members of the patient.

Exclusion criteria

Exclusion criteria: 1. Secondary hypertension such as aldosteronism, pheochromocytoma, Cushing syndrome, pregnancy hypertension and so on; 2. Patients with other serious complications such as cardio-cerebral vessels, kidney, retina, peripheral blood vessels, diabetes, blood diseases, etc., which are not suitable for acupuncture treatment; 3. Patients with skin diseases and skin damage at the tested acupoints; 4. Women with mental illness or pregnancy or lactation; 5. Complicated with diagnosed epilepsy, obstructive sleep apnea hypopnea syndrome and so on; 6. Those who are participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Ambulatory blood pressure monitoring;

Countries

China

Contacts

Public ContactZhao Jiping

Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine

Zjp7883@sina.com+86 010 84013161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026